• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用Urolastic®进行尿道旁注射治疗女性压力性尿失禁:主观改善情况与安全性

Para-Urethral Injections with Urolastic® for Treatment of Female Stress Urinary Incontinence: Subjective Improvement and Safety.

作者信息

de Vries Allert M, van Breda Hendrikje M K, Fernandes Jimmy G, Venema Pieter L, Heesakkers John P F A

机构信息

Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands.

出版信息

Urol Int. 2017;99(1):91-97. doi: 10.1159/000452450. Epub 2017 Feb 3.

DOI:10.1159/000452450
PMID:28152525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5637293/
Abstract

INTRODUCTION

Female stress urinary incontinence (SUI) is often treated surgically. Urethral bulking agents are a minimally invasive alternative, especially in patients suffering from intrinsic sphincter deficiency, but often with limited long-term efficacy. Urolastic® is a non-deformable, non-resorbable silicone elastomer that is used as an injectable. Its properties might result in a more durable response after injection. If this durability factor can be combined with a low complication rate, this can become a useful treatment option. We therefore assessed the subjective improvement and safety after treatment with Urolastic®.

MATERIALS AND METHODS

In 2 Dutch hospitals, 65 patients were treated with Urolastic®. The subjective improvement was assessed and the medical charts were reviewed for complications that appeared during the follow-up period. The complications were classified using the Clavien-Dindo classification.

RESULTS

We found that 76-88% of the patients showed subjective improvement at 12-25 months follow-up. The rate of improvement experienced was 50-70%. The rate of complications classified as Clavien-Dindo >II was 24-33%. The 12 patients with 75-100% subjective improvement after 2 months, showed 85% improvement after a median of 25 months.

CONCLUSIONS

With careful patient selection, Urolastic® seems to be a safe, durable and effective treatment option for female SUI.

摘要

引言

女性压力性尿失禁(SUI)通常采用手术治疗。尿道填充剂是一种微创替代方法,尤其适用于患有内在括约肌缺陷的患者,但长期疗效往往有限。Urolastic®是一种不可变形、不可吸收的硅酮弹性体,用作注射剂。其特性可能导致注射后反应更持久。如果这种持久性因素能与低并发症发生率相结合,那么它可能成为一种有用的治疗选择。因此,我们评估了使用Urolastic®治疗后的主观改善情况和安全性。

材料与方法

在荷兰的两家医院,65例患者接受了Urolastic®治疗。评估主观改善情况,并查阅病历以了解随访期间出现的并发症。使用Clavien-Dindo分类法对并发症进行分类。

结果

我们发现,76% - 88%的患者在12 - 25个月的随访中显示出主观改善。改善率为50% - 70%。Clavien-Dindo分级>II级的并发症发生率为24% - 33%。2个月后主观改善率为75% - 100%的12例患者,在中位25个月后改善率为85%。

结论

经过仔细的患者选择,Urolastic®似乎是女性SUI的一种安全、持久且有效的治疗选择。

相似文献

1
Para-Urethral Injections with Urolastic® for Treatment of Female Stress Urinary Incontinence: Subjective Improvement and Safety.使用Urolastic®进行尿道旁注射治疗女性压力性尿失禁:主观改善情况与安全性
Urol Int. 2017;99(1):91-97. doi: 10.1159/000452450. Epub 2017 Feb 3.
2
Nonabsorbable urethral bulking agent - clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up.不可吸收性尿道填充剂——2年随访后治疗复发性压力性尿失禁的临床疗效及晚期并发症发生率
Eur J Obstet Gynecol Reprod Biol. 2016 Dec;207:68-72. doi: 10.1016/j.ejogrb.2016.10.011. Epub 2016 Oct 26.
3
An Open Multicenter Study of Clinical Efficacy and Safety of Urolastic, an Injectable Implant for the Treatment of Stress Urinary Incontinence: One-Year Observation.一项关于Urolastic(一种用于治疗压力性尿失禁的可注射植入物)临床疗效和安全性的开放性多中心研究:一年观察期
Biomed Res Int. 2015;2015:851823. doi: 10.1155/2015/851823. Epub 2015 Apr 20.
4
Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis.新型填充剂Urolastic®治疗压力性尿失禁的系统评价与Meta分析
Int Urogynecol J. 2018 Sep;29(9):1239-1247. doi: 10.1007/s00192-018-3703-6. Epub 2018 Jun 23.
5
Two Cases of Suspected Rejection of Polydimethylsiloxane Urethral Bulking Agent.两例聚二甲基硅氧烷尿道填充剂疑似排斥反应病例
Female Pelvic Med Reconstr Surg. 2017 May/Jun;23(3):e10-e11. doi: 10.1097/SPV.0000000000000367.
6
Urethral bulking agents for female stress urinary incontinence.尿道填充剂治疗女性压力性尿失禁。
Neurourol Urodyn. 2019 Mar;38(3):887-892. doi: 10.1002/nau.23924. Epub 2019 Feb 22.
7
Results of an innovative bulking agent in patients with stress urinary incontinence who are not optimal candidates for mid-urethral sling surgery.一种新型膨体材料在非中尿道吊带术最佳候选患者中的压力性尿失禁治疗效果。
Neurourol Urodyn. 2018 Jan;37(1):339-345. doi: 10.1002/nau.23299. Epub 2017 Apr 28.
8
Can Urethral Bulking Agents Salvage Failed Slings?尿道填充剂能挽救失败的吊带手术吗?
Urology. 2019 Feb;124:78-82. doi: 10.1016/j.urology.2018.09.019. Epub 2018 Nov 7.
9
Intraurethral bulking agents for the management of female stress urinary incontinence: a systematic review.用于治疗女性压力性尿失禁的尿道内填充剂:一项系统评价
Int Urogynecol J. 2017 Sep;28(9):1275-1284. doi: 10.1007/s00192-017-3278-7. Epub 2017 Feb 21.
10
Patients' satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: A cross-sectional study.患者对注射治疗逼尿肌不稳定的满意度和安全性:一项横断面研究。
Neurourol Urodyn. 2020 Aug;39(6):1753-1763. doi: 10.1002/nau.24417. Epub 2020 Jun 11.

引用本文的文献

1
Current Treatment of Stress Urinary Incontinence by Bulking Agents and Laser Therapy-An Update.填充剂和激光疗法治疗压力性尿失禁的现状——最新进展
J Clin Med. 2024 Feb 28;13(5):1377. doi: 10.3390/jcm13051377.
2
Update on Urethral Bulking for Stress Urinary Incontinence in Women.女性压力性尿失禁尿道填充治疗进展。
Curr Urol Rep. 2022 Oct;23(10):203-209. doi: 10.1007/s11934-022-01099-5. Epub 2022 Jul 4.
3
Urethral Bulking in the Treatment of Stress and Mixed Female Urinary Incontinence: Results from a Multicenter Cohort and Predictors of Clinical Outcomes.尿道填充术治疗女性压力性和混合性尿失禁:多中心队列研究结果及临床结局预测因素
J Clin Med. 2022 Mar 12;11(6):1569. doi: 10.3390/jcm11061569.
4
Imaging findings of vinyl dimethyl polydimethylsiloxane used as a paraurethral injectable for female stress urinary incontinence.用作女性压力性尿失禁尿道旁注射剂的乙烯基二甲基聚二甲基硅氧烷的影像学表现。
Ther Adv Urol. 2021 Dec 5;13:17562872211060909. doi: 10.1177/17562872211060909. eCollection 2021 Jan-Dec.
5
Patients' satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: A cross-sectional study.患者对注射治疗逼尿肌不稳定的满意度和安全性:一项横断面研究。
Neurourol Urodyn. 2020 Aug;39(6):1753-1763. doi: 10.1002/nau.24417. Epub 2020 Jun 11.
6
Particulate Versus Non-Particulate Bulking Agents In The Treatment Of Stress Urinary Incontinence.颗粒状与非颗粒状填充剂治疗压力性尿失禁的比较
Res Rep Urol. 2019 Nov 12;11:299-310. doi: 10.2147/RRU.S220216. eCollection 2019.
7
Contemporary diagnostics and treatment options for female stress urinary incontinence.女性压力性尿失禁的当代诊断与治疗选择
Asian J Urol. 2018 Jul;5(3):141-148. doi: 10.1016/j.ajur.2017.09.001. Epub 2017 Sep 14.
8
Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis.新型填充剂Urolastic®治疗压力性尿失禁的系统评价与Meta分析
Int Urogynecol J. 2018 Sep;29(9):1239-1247. doi: 10.1007/s00192-018-3703-6. Epub 2018 Jun 23.

本文引用的文献

1
The Correlation of Urethral Pressure Profilometry Data in Women with Different Types of Urinary Incontinence.
Urol Int. 2016;97(2):218-23. doi: 10.1159/000445807. Epub 2016 Apr 14.
2
A Valuable Option in the Management of Female Recurrent Stress Urinary Incontinence: Re-Adjustable Sling (Remeex Sling System).女性复发性压力性尿失禁管理中的一个有价值选择:可重新调整的吊带(Remeex吊带系统)
Urol Int. 2016;97(2):224-9. doi: 10.1159/000444398. Epub 2016 Feb 20.
3
Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature.用于女性压力性尿失禁的聚丙烯酰胺水凝胶(Bulkamid®):文献系统评价
Int Urogynecol J. 2016 Mar;27(3):367-75. doi: 10.1007/s00192-015-2781-y. Epub 2015 Jul 26.
4
Mid-urethral sling operations for stress urinary incontinence in women.女性压力性尿失禁的中段尿道吊带手术
Cochrane Database Syst Rev. 2015 Jul 1(7):CD006375. doi: 10.1002/14651858.CD006375.pub3.
5
An Open Multicenter Study of Clinical Efficacy and Safety of Urolastic, an Injectable Implant for the Treatment of Stress Urinary Incontinence: One-Year Observation.一项关于Urolastic(一种用于治疗压力性尿失禁的可注射植入物)临床疗效和安全性的开放性多中心研究:一年观察期
Biomed Res Int. 2015;2015:851823. doi: 10.1155/2015/851823. Epub 2015 Apr 20.
6
Guideline of guidelines: urinary incontinence.指南之指南:尿失禁
BJU Int. 2016 Jan;117(1):20-33. doi: 10.1111/bju.13187. Epub 2015 Jul 1.
7
Urethral bulking agents versus other surgical procedures for the treatment of female stress urinary incontinence: a systematic review and meta-analysis.尿道填充剂与其他外科手术治疗女性压力性尿失禁的比较:一项系统评价和荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2015 Jun;189:48-54. doi: 10.1016/j.ejogrb.2015.03.025. Epub 2015 Mar 28.
8
Urolastic-a new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up.Urolastic——一种用于治疗女性压力性尿失禁的新型填充剂:12个月随访结果
Adv Urol. 2013;2013:724082. doi: 10.1155/2013/724082. Epub 2013 Dec 22.
9
Use of Clavien-Dindo classification in reporting and grading complications after urological surgical procedures: analysis of 2010 to 2012.使用 Clavien-Dindo 分类报告和分级泌尿外科手术后并发症:2010 年至 2012 年分析。
J Urol. 2013 Oct;190(4):1271-4. doi: 10.1016/j.juro.2013.04.025. Epub 2013 Apr 11.
10
Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents.用于治疗压力性尿失禁的可注射生物材料:其作为尿道填充剂的潜力与缺陷
Int Urogynecol J. 2013 Jun;24(6):913-9. doi: 10.1007/s00192-012-2011-9. Epub 2012 Dec 8.